335 related articles for article (PubMed ID: 7842711)
41. Pretreatment with topical 0.1% (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine inhibits adenovirus type 5 replication in the New Zealand rabbit ocular model.
Gordon YJ; Romanowski E; Araullo-Cruz T; De Clercq E
Cornea; 1992 Nov; 11(6):529-33. PubMed ID: 1334824
[TBL] [Abstract][Full Text] [Related]
42. Effect of Azone upon the in vivo antiviral efficacy of cidofovir or acyclovir topical formulations in treatment/prevention of cutaneous HSV-1 infections and its correlation with skin target site free drug concentration in hairless mice.
Afouna MI; Fincher TK; Zaghloul AA; Reddy IK
Int J Pharm; 2003 Mar; 253(1-2):159-68. PubMed ID: 12593946
[TBL] [Abstract][Full Text] [Related]
43. In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model.
Anand BS; Hill JM; Dey S; Maruyama K; Bhattacharjee PS; Myles ME; Nashed YE; Mitra AK
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2529-34. PubMed ID: 12766053
[TBL] [Abstract][Full Text] [Related]
44. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model.
Romanowski EG; Yates KA; Gordon YJ
Antiviral Res; 2001 Dec; 52(3):275-80. PubMed ID: 11675144
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of topical immunoglobulins against experimental adenoviral ocular infection.
Nwanegbo EC; Romanowski EG; Gordon YJ; Gambotto A
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4171-6. PubMed ID: 17724203
[TBL] [Abstract][Full Text] [Related]
46. The effects of Xalatan on the recovery of ocular herpes simplex virus type 1 (HSV-1) in the induced reactivation and spontaneous shedding rabbit models.
Gordon YJ; Yates KA; Mah FS; Romanowski EG
J Ocul Pharmacol Ther; 2003 Jun; 19(3):233-45. PubMed ID: 12828841
[TBL] [Abstract][Full Text] [Related]
47. Efficient reactivation of latent herpes simplex virus type 1 infection by excimer laser keratectomy in the experimental rabbit ocular model.
Dhaliwal DK; Barnhorst DA; Romanowski E; Rehkopf PG; Gordon YJ
Am J Ophthalmol; 1998 Apr; 125(4):488-92. PubMed ID: 9559734
[TBL] [Abstract][Full Text] [Related]
48. [Comparison of therapeutic activity of idoxuridine and acyclovir in experimentally-induced herpetic keratitis in rabbits (author's transl)].
Colin C; Chastel C; Quillien MC; Renard G
J Fr Ophtalmol; 1981; 4(1):33-43. PubMed ID: 7217623
[TBL] [Abstract][Full Text] [Related]
49. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) inhibits HIV-1 replication in epithelial cells, but not T-lymphocytes.
Srinivas RV; Connely M; Fridland A
Antiviral Res; 1997 Jun; 35(1):23-7. PubMed ID: 9224958
[TBL] [Abstract][Full Text] [Related]
50. [Study on the inhibitory effect of cepharanthine on herpes simplex type-1 virus (HSV-1) in vitro].
Liu X; Wang Y; Zhang M; Li G; Cen Y
Zhong Yao Cai; 2004 Feb; 27(2):107-10. PubMed ID: 22454997
[TBL] [Abstract][Full Text] [Related]
51. Clinical characteristics of acyclovir-resistant herpetic keratitis and experimental studies of isolates.
Yao YF; Inoue Y; Kase T; Uchihori Y; Mori Y; Ohashi Y
Graefes Arch Clin Exp Ophthalmol; 1996 Aug; 234 Suppl 1():S126-32. PubMed ID: 8871163
[TBL] [Abstract][Full Text] [Related]
52. Isolation of human adenovirus type 5 variants resistant to the antiviral cidofovir.
Gordon YJ; Araullo-Cruz TP; Johnson YF; Romanowski EG; Kinchington PR
Invest Ophthalmol Vis Sci; 1996 Dec; 37(13):2774-8. PubMed ID: 8977495
[TBL] [Abstract][Full Text] [Related]
53. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo.
Liuzzi M; Déziel R; Moss N; Beaulieu P; Bonneau AM; Bousquet C; Chafouleas JG; Garneau M; Jaramillo J; Krogsrud RL
Nature; 1994 Dec; 372(6507):695-8. PubMed ID: 7990963
[TBL] [Abstract][Full Text] [Related]
54. Effect of famciclovir on herpes simplex virus type 1 corneal disease and establishment of latency in rabbits.
Loutsch JM; Sainz B; Marquart ME; Zheng X; Kesavan P; Higaki S; Hill JM; Tal-Singer R
Antimicrob Agents Chemother; 2001 Jul; 45(7):2044-53. PubMed ID: 11408221
[TBL] [Abstract][Full Text] [Related]
55. Assessment of acyclovir on acute ocular infection induced by drug-resistant strains of HSV-1.
Trousdale MD; Nesburn AB; Miller CA
Invest Ophthalmol Vis Sci; 1981 Feb; 20(2):230-5. PubMed ID: 6257622
[TBL] [Abstract][Full Text] [Related]
56. Antiviral effects of Cacicol
Deback C; Rousseau A; Breckler M; Molet L; Boutolleau D; Burrel S; Roque-Afonso AM; Labetoulle M
Antivir Ther; 2018; 23(8):665-675. PubMed ID: 30028308
[TBL] [Abstract][Full Text] [Related]
57. DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions.
Andrei G; Fiten P; Froeyen M; De Clercq E; Opdenakker G; Snoeck R
Antivir Ther; 2007; 12(5):719-32. PubMed ID: 17713155
[TBL] [Abstract][Full Text] [Related]
58. Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections.
Carmine AA; Brogden RN; Heel RC; Speight TM; Avery GS
Drugs; 1982 May; 23(5):329-53. PubMed ID: 6284470
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of polyclonal antibodies for treatment of ocular herpes simplex infection.
Epstein SP; Nurozler M; Smetana CR; Asbell PA
Cornea; 2001 Jul; 20(5):495-500. PubMed ID: 11413405
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice.
De Clercq E; Holý A
Antimicrob Agents Chemother; 1991 Apr; 35(4):701-6. PubMed ID: 2069375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
